2. Metabolic Enzyme/Protease NF-κB Anti-infection
  3. Endogenous Metabolite NF-κB Bacterial
  4. Myristic acid

Myristic acid is an orally active saturated 14-carbon fatty acid found in most animal and plant fats, especially milk fat coconut oil, palm oil and nutmeg oil. Myristic acid exerts anti-inflammatory activity through the NF-κB pathway. Myristic acid has antibacterial, anti-inflammatory and analgesic properties.

For research use only. We do not sell to patients.

Myristic acid Chemical Structure

Myristic acid Chemical Structure

CAS No. : 544-63-8

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
500 mg USD 50 In-stock
1 g USD 60 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Myristic acid:

Myristic acid Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Myristic acid is an orally active saturated 14-carbon fatty acid found in most animal and plant fats, especially milk fat coconut oil, palm oil and nutmeg oil. Myristic acid exerts anti-inflammatory activity through the NF-κB pathway. Myristic acid has antibacterial, anti-inflammatory and analgesic properties[1][2][3][4].

IC50 & Target

Human Endogenous Metabolite

 

Cellular Effect
Cell Line Type Value Description References
CHO EC50
11.4 μM
Compound: 20
Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m
Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m
[PMID: 31721581]
CHO EC50
7.01 μM
Compound: 20
Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay
Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay
[PMID: 31721581]
Huh-7 CC50
> 50 μM
Compound: Myristic acid
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by CellTiter-Glo analysis
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by CellTiter-Glo analysis
[PMID: 34583312]
In Vitro

Myristic acid (100, 150, 200 μM, 24 h) regulates the production of triglyceride in bovine mammary epithelial cells through ubiquitination pathway[1].
Myristic acid (3-1000 μM, 10 min) can inhibit the activity of bacterial ABC transporter BmrA[2].
Myristic acid (12.5-200 μg/mL, 24 h) exerts in vitro anti-inflammatory activity by increasing (58%) IL-10 production in LPS (HY-D1056)-stimulated macrophages[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Myristic acid Related Antibodies

Western Blot Analysis[1]

Cell Line: MAC-T
Concentration: 100, 150, 200 μM
Incubation Time: 24 h
Result: Increased the level of protein ubiquitination.

Cell Viability Assay[3]

Cell Line: J774A.1 macrophages
Concentration: 12.5, 25, 50, 100,200 μg/mL
Incubation Time: 24 h
Result: Showed non-cytotoxic effects in LPS-stimulated J774A.1 macrophages at 25 μg/mL.
In Vivo

Myristic acid (12.5-100 mg/kg, orally, Single dose) has good anti-inflammatory effect on ear edema induced by acute (ED50 = 62 mg/kg) and chronic (ED50 = 77 mg/kg) mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: TPA-induced ear edema in mice[3]
Dosage: 12.5, 25, 50, 100 mg/kg
Administration: p.o.
Result: Decreased ear edema inflammation in the acute and chronic TPA assays with IC50 values of 62 and 77 mg/kg, respectively in a dose-dependent manner.
Attenuated the acetic acid-induced abdominal contortions with ED50 values of 32 mg/kg.
Molecular Weight

228.37

Formula

C14H28O2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCCCCCCCC(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 200 mg/mL (875.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 100 mg/mL (437.89 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.3789 mL 21.8943 mL 43.7886 mL
5 mM 0.8758 mL 4.3789 mL 8.7577 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 5 mg/mL (21.89 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 5 mg/mL (21.89 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  Cremophor EL

    Solubility: 40 mg/mL (175.15 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: ≥98.0%

SDS (393 KB)

COA (238 KB) HNMR (239 KB) MS (80 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 4.3789 mL 21.8943 mL 43.7886 mL 109.4715 mL
5 mM 0.8758 mL 4.3789 mL 8.7577 mL 21.8943 mL
10 mM 0.4379 mL 2.1894 mL 4.3789 mL 10.9471 mL
15 mM 0.2919 mL 1.4596 mL 2.9192 mL 7.2981 mL
20 mM 0.2189 mL 1.0947 mL 2.1894 mL 5.4736 mL
25 mM 0.1752 mL 0.8758 mL 1.7515 mL 4.3789 mL
30 mM 0.1460 mL 0.7298 mL 1.4596 mL 3.6490 mL
40 mM 0.1095 mL 0.5474 mL 1.0947 mL 2.7368 mL
50 mM 0.0876 mL 0.4379 mL 0.8758 mL 2.1894 mL
60 mM 0.0730 mL 0.3649 mL 0.7298 mL 1.8245 mL
80 mM 0.0547 mL 0.2737 mL 0.5474 mL 1.3684 mL
100 mM 0.0438 mL 0.2189 mL 0.4379 mL 1.0947 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Myristic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Myristic acid544-63-8Endogenous MetaboliteNF-κBBacterialNuclear factor-κBNuclear factor-kappaBAnti-inflammatoryAntibacterialMAC-TJ774A.1 macrophagesEar edemaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Myristic acid
Cat. No.:
HY-N2041
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.